𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone

✍ Scribed by A. Corso; A. Lorenzi; V. Terulla; F. Airò; M. Varettoni; S. Mangiacavalli; P. Zappasodi; C. Rusconi; M. Lazzarino

Publisher
Springer
Year
2004
Tongue
English
Weight
67 KB
Volume
83
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The combination of intermediate doses of
The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma
✍ E. Hatjiharissi; E. Terpos; M. Papaioannou; C. Hatjileontis; V. Kaloutsi; G. Gal 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB

## Abstract The aim of the study was the evaluation of anti‐angiogenic activity of the combination of intermediate doses of thalidomide and dexamethasone in patients with refractory/relapsed myeloma. Twenty‐five patients were included in the study. Microvessel density (MVD) was evaluated in marrow